#United States #San Diego #Deck Bio #DBXO-1 #T Cell Engager

Deck Bio Presents Unique T Cell Engager Approach at Major Conferences

Deck Bio, a pioneer in biotechnology focused on developing multi-pMHC targeted T cell engagers for treating solid tumors, is gearing up for significant presentations at the upcoming 8th T-Cell Engager Therapeutics Summit and the BIO International Convention 2026, both in San Diego, California. This participation will mark a vital opportunity for the company to share advancements in its innovative therapeutic platform designed to address the challenges in solid tumor treatment, which has been historically more complex than hematologic malignancies.

The solid tumor market poses significant hurdles for immunotherapy, especially in targeting cancer cells effectively while minimizing damage to healthy tissue. This complexity has led Deck Bio to devise the DBXO-1, a game-changing multi-pMHC targeted T cell engager that utilizes a singular engineered T cell receptor (TCR)-based binder. This novel design empowers DBXO-1 to recognize multiple cancer-associated peptide–major histocompatibility complexes (pMHCs) concurrently, expanding patient eligibility and enhancing the likelihood of sustained therapeutic response across a selection of prominent solid tumor indications. The innovation could transform the landscape of oncological therapies by improving accessibility and treatment longevity for patients.

Jack Silberstein, CEO and Founder of Deck Bio, reflected on the importance of these conferences, noting, "The success of T cell engagers in hematologic malignancies has spurred interest in applying similar strategies to solid tumors. However, to succeed, it requires fresh perspectives on targeting biology and therapeutic framework development. This platform allows for such discussions and highlights our progress with DBXO-1."

Conference Details and Presentations

8th T-Cell Engager Therapeutics Summit

• - Date: June 23-25, 2026
• - Location: Westin San Diego Bayview
• - Featured Workshop: "Synchronizing Global Regulatory Strategies through Modelling: Translational Approaches for Next-Generation TCEs" on June 23 from 2:00 - 4:00 p.m. PT
• - Scientific Presentation: "Expanding the Reach of T Cell Engagers in Solid Tumors through pMHC Multi-Targeting" on June 24 from 2:00 - 2:30 p.m. PT

BIO International Convention 2026

• - Date: June 22-25, 2026
• - Location: San Diego Convention Center
• - Start-Up Stadium Pitch: Deck Bio on June 23 from 2:00 - 4:00 p.m. PT
• - Panel Discussion: "The Therapeutic Modality Puzzle in Oncology: One Size Fits All or Fit to Purpose?" on June 24 from 4:15 - 5:15 p.m. PT

Throughout both conferences, members of Deck Bio's leadership team will be accessible for scientific discussions and potential partnerships, aiming to further collaborations that can expedite their innovative work in cancer therapy.

About Deck Bio

Founded and headquartered in Cambridge, Massachusetts, Deck Bio stands at the forefront of biotechnological advancements in cancer therapies. The company is dedicated to developing pioneer immunotherapies capable of enhancing the effectiveness and safety of T cell engagers specifically for solid tumors. By leveraging its proprietary technologies, such as dbTv™ for T cell receptor stabilization and dbSCOPE™ for peptidome-wide specificity profiling, Deck Bio is relentlessly pursuing innovative solutions to meet the considerable unmet needs in oncology. The goal is to revolutionize cancer treatment by unlocking the potential of T cell engagers with a robust and patient-centric approach. For additional details about their missions and programs, interested parties may visit deck.bio or follow them on LinkedIn.